Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"EpiPharm","sponsor":"CalciMedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CalciMedica Enters Research Pact with EpiPharma to Discover and Develop CRAC Channel Inhibitor Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"EpiPharm"},{"company":"Novartis Pharmaceuticals Corporation","sponsor":"Boston Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"company":"Alentis Therapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alentis Therapeutics Raises USD 67 Million in Series B Financing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alentis Therapeutics"}]

Alentis Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Alentis Therapeutics Raises USD 67 Million in Series B Financing

Details:

Alentis’ lead molecules ALE.F02 and ALE.C04 are highly selective anti-Claudin-1 mAb that recognize pathological overexpressed and conformation-dependent Claudin-1 epitopes in fibrotic disease and cancer.

Lead Product(s): ALE.F02

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Morningside Venture

Deal Size: $67.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing June 15, 2021

ASK
US

Upload
your Pipeline Activity

Novartis Pharmaceuticals Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis

Details:

Under the terms of the agreement, Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH) from Novartis.

Lead Product(s): BOS-580

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BOS-580

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Boston Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement September 01, 2020

ASK
US

Upload
your Pipeline Activity

EpiPharm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CalciMedica Enters Research Pact with EpiPharma to Discover and Develop CRAC Channel Inhibitor Therapies

Details:

CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.

Lead Product(s): CM5480

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM5480

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: CalciMedica

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 21, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY